Le Lézard
Classified in: Health
Subjects: LEG, POL, VET

Veteran's Health Bill Included in End-of-Year Spending Package


BALTIMORE, Dec. 23, 2022 /PRNewswire/ -- The American Urological Association (AUA) today celebrates the inclusion of the Veteran's Prostate Cancer Treatment and Research Act in Congress' end of year spending package. This important bill supports the development and implementation of a Veterans Health Administration (VHA) healthcare program focused on coordinated and comprehensive care for veterans with prostate cancer.

The bill also directs the VHA to develop a national clinical pathway for prostate cancer and to design a Prostate Cancer Registry and Research Program. A clinical pathway is a tool based on multidisciplinary evidence that guides healthcare best practices for a specific condition or disease. The goal of a clinical pathway is to streamline and improve both quality and delivery of care for patients, resulting in improved outcomes for those patients. The registry created by this legislation would be specific to veterans receiving treatment within the VHA system.

The American Cancer Society estimates that more than 268,000 people were diagnosed with prostate cancer in 2022 alone. In addition, the National Institutes of Health reports that prostate cancer is the most common cancer diagnosed in the VHA. Thus, for the past several years, the AUA and its advocacy partners have been committed to finding a process to improve prostate cancer care for our nation's veterans.

"Over the last two congresses, the AUA has worked closely with patient advocacy organizations such as Veterans Prostate Cancer Awareness, Prostate Cancer Foundation and ZERO ? The End of Prostate Cancer to draft the legislation, find bill champions in both the U.S. House and Senate and usher it through the legislative process," said Robert Bass, MD, chair of the AUA's Legislative Affairs Committee. "As prostate cancer continues to be a growing problem amongst our veteran population, it is our hope that the VHA will be well-positioned to develop these clinical pathway models and improve research and evidence-based treatments for veterans across America."

The AUA applauds the leadership of Senators Jerry Moran (R-KS) and Jon Tester (D-MT) as well as Representatives Neal Dunn, MD, (R-FL-02) and Elissa Slotkin (D-MI-08) on this important issue.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Media Contact:
Rachel Butch, Corporate Communications and Media Relations Manager
410-689-4033, [email protected]

SOURCE American Urological Association


These press releases may also interest you

at 11:55
The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K...

at 11:30
The National Alliance on Mental Illness Greater L.A. County (NAMI GLAC) will celebrate its 20th annual NAMIWalks Greater LA County Mental Health Festival during Mental Health Awareness Month on Saturday, May 4, 2024. This free community wide event at...

at 10:30
Flourishing Foundations Recovery has launched a new outpatient detox center in San Antonio, TX, aiming to help individuals tackle drug and alcohol addiction without pausing their daily lives. The new substance abuse treatment center ensures easy...

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...



News published on and distributed by: